摘要
Abstract
OBJECTIVE:To observe the efficacy and safety of methylprednisolone combined with entecavir in the treatment of primary nephrotic syndrome with hepatitis B virus infection. METHODS:23 primary nephrotic syndrome patients with hepatitis B virus infection were given 0.5 mg/times Entecavir tablet,orally,once a day,for 2 weeks,and added 0.8mg/(kg.d)Methylpredniso-lone tablet,orally,once a day,for 8 weeks,then the dose was maintained for 2-3 months every other day,and then decreased 4 mg for 4 weeks every other day,and the dose was decreased 4 mg every 2-4 weeks,until drug withdrawal. Entecavir tablet was used in the whole process of Methylprednisolone tablet,the dose was adjusted and gradually stopped based on HBV-DNA within 3 months of Entecavir tablet withdrawal. Liver and renal efficacy,24 h urine protein excretion,serum albumin(ALB),alanine ami-notransferase(ALT),aspartate aminotransferase(AST)levels before and after treatment of 2,6,12 and 15 months,and the inci-dence of adverse reactions of all patients were observed. RESULTS:The liver and renal efficacy were 100%;after treatment of 2, 6,12 and 15 months,24 h urine protein,ALT and AST were significantly lower than before and gradually decreased by time, ALB was significantly higher than before and gradually increased by time,the differences were statistically significant(P<0.05);the incidence of adverse reactions was 43.48%,and there were no obvious adverse reactions and no renal dysfunction. CONCLU-SIONS:Methylprednisolone combined with entecavir has significant efficacy in the treatment of primary nephrotic syndrome with hepatitis B virus infection,with good safety.关键词
甲泼尼龙/恩替卡韦/原发性肾病综合征/乙型肝炎病毒感染Key words
Methylprednisolone/Entecavir/Primary nephrotic syndrome/Hepatitis B virus infection分类
医药卫生
